A Comparison Between Dabigatran and Warfarin on Time to Elective Cardioversion

Area of Science:

• Cardiology
• Pharmacology
• Medical Research

Background:

• Atrial fibrillation and atrial flutter necessitate anticoagulation for procedures like direct current cardioversion (DCCV).
• Warfarin has been a traditional anticoagulant, but newer agents like dabigatran offer alternative therapeutic options.
• Optimizing the timing and efficiency of DCCV is crucial for patient management and outcomes.

Purpose of the Study:

• To compare the efficacy of dabigatran versus warfarin in achieving timely elective direct current cardioversion (DCCV).
• To evaluate secondary outcomes including therapy costs, procedure rescheduling rates, and adverse events associated with each anticoagulant.

Main Methods:

• A retrospective observational study analyzed 68 male patients (average age 68) with atrial fibrillation or flutter undergoing DCCV.
• Patients were initiated on either warfarin or dabigatran prior to DCCV.
• Time to cardioversion, costs, rescheduling rates, and adverse events were compared between the two anticoagulant groups.

Main Results:

• Dabigatran use resulted in a significantly shorter median time to cardioversion (34.5 days) compared to warfarin (66.5 days) (p<0.01).
• No significant difference in CHADS2 or HASBLED scores was observed between groups.
• The dabigatran group had no DCCV reschedulings, unlike the warfarin group (3/30 patients). One bleeding event occurred in the warfarin group; no thromboembolic events were reported in either group.

Conclusions:

• Dabigatran is associated with a significantly faster time to elective DCCV compared to warfarin.
• While dabigatran incurs slightly higher costs, it demonstrates potential benefits in reducing procedure delays and rescheduling rates.
• Further research may explore long-term outcomes and cost-effectiveness in diverse patient populations.